CHA Biotech (085660) Stock Overview

CHA Biotech Co., Ltd., together with its subsidiaries, engages in cell therapy development, cord blood, and stem cell banking services. The company operates a cord blood consignment storage business for the treatment of intractable diseases, as well as provides regenerative medicines, Immune and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs comprising fitness, spa, and supplements; and customized development, production, clinical, and commercialization services to customers with research and development, and clinical experience. It also offers optimized IT system construction and operation; consulting services for development, operation, and expansion of Chaum model; and solutions for maternal-centered genome testing and personalized healthcare. The company operates in South Korea, Singapore, Indonesia, the United States, Japan, Australia, and Vietnam. CHA Biotech Co., Ltd. was founded in 2002 and is headquartered in Seongnam-si, South Korea.